India pharma retail volumes cross 3% in June, first time in 24 months
The Rs 2.5 lakh crore pharma retail market is showing a demand-led recovery, with June volume growth topping 3% after two flat years. Full-year outlook revised up to over 11% from 8-9%, driven by cardiac, chronic and anti-cancer therapies. Organised segment posts 13% value growth.
What happened
Pharmarack · India's Rs 2.5 lakh crore pharma retail market shows demand-led recovery, with June volume growth crossing 3% for first time in 24 months.
Key facts
- 3% volume growth in June
- 1-2% first five months
- outlook revised to over 11% from 8-9%
- 8% growth last year
- over Rs 2.5 lakh crore market
- 13% value growth organised segment
Why this matters
Accelerating volumes and organised-segment outperformance make now an opportune window to consolidate fragmented retail assets in chronic and anti-cancer-focused pharmacies.
What to watch
- July-August volume prints confirming trend vs seasonal blip
- NPPA/NLEM price revision announcements affecting margins
- Rural consumption and monsoon data
- Organised segment monthly value growth vs standalone
- Anti-cancer and specialty therapy access/pricing policy
- Pharma distributors and chains expand chronic/cardiac SKU inventory and cold-chain for anti-cancer therapies
- Organised players push subscription/refill models to lock chronic patients
- FMCG-adjacent players and PE watch for acquisition of regional pharmacy networks
- Manufacturers revise volume guidance upward and reprioritize chronic portfolios